Key points are not available for this paper at this time.
As compared with the standard regimen of cisplatin and fluorouracil, induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00003888 ClinicalTrials.gov.).
Vermorken et al. (Wed,) studied this question.